MORE►
periprosthetic joint infection
Osteal Therapeutics Chairman and CEO David Thompson spoke on the company's lead candidate at LSI Europe ‘23 Emerging Medtech Summit last fall.
Dallas Biotech Secures $50M Series D Funding To Combat Rare Hidden Killer in Joint Replacements
by Quincy Preston | Jul 16, 2024
The $50 million funding will support the commercial launch of Osteal Therapeutics' pioneering combination drug/device therapy targeting biofilm infections, which are notoriously difficult to eradicate.
by Lance Murray |
Sep 21, 2023
Osteal Therapeutics, a clinical-stage biopharmaceutical company, says it's developing "a new category" of combination therapies for orthopedic infections. The new funding round, led by Asteroid Partners, will help Osteal accelerate preparation for commercial launch of VT-X7, its lead therapy for the treatment of periprosthetic joint infection, the company said.
MORE►
